Mammoscintigraphy with Technetium-99m-Sestamibi in Suspected Breast Cancer

J. Villanueva-Meyer, M. H. Leonard, E. Briscoe, F. Cesani, S. A. Ali, S. Rhoden, M. Hove, D. Cowan

Research output: Contribution to journalArticlepeer-review

127 Scopus citations


Our goal was to determine the clinical usefulness of 99mTc-sestamibi to identify breast cancer in patients prior to biopsy. Methods: We studied 66 patients who received 20 mCi 99mTc-sestamibi intravenously. Lateral and anterior planar images were gathered within 30 min of the injection. Only focal increased uptake was interpreted as positive. Confirmatory pathologic diagnoses were obtained within 2 mo. The prevalence of breast cancer in our sample was 54%. Results: We report an overall sensitivity of 83% and specificity of 93% for the diagnosis of breast cancer. In palpable lesions, the sensitivity was of 94% with a specificity of 91%, while in nonpalpable abnormalities the sensitivity was of 64% with a 100% specificity. Six patients with a malignancy had negative scans, four of these lesions were nonpalpable. Only two of 31 patients with benign lesions had an abnormal scan. Conclusion: Mammoscintigraphy with 99mTc-sestamibi has high specificity and adequate sensitivity for the noninvasive diagnosis of breast carcinomas.

Original languageEnglish (US)
Pages (from-to)926-930
Number of pages5
JournalJournal of Nuclear Medicine
Issue number6
StatePublished - 1996


  • Breast cancer
  • Technetium-99m-sestamibi

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology


Dive into the research topics of 'Mammoscintigraphy with Technetium-99m-Sestamibi in Suspected Breast Cancer'. Together they form a unique fingerprint.

Cite this